Physician profile
David Krendel
NPI 1568463370
$1,472.26
in general payments reported to CMS, 2019-2025
31 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $257 · 2021: $269 · 2022: $177 · 2023: $157 · 2024: $135 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $176.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $147.06 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $145.10 | 2021-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $95.19 | 2019-2020 | |
| Sk Life Science, INC. | $89.66 | 2020-2022 | |
| Banner Life Sciences, LLC | $81.18 | 2023-2024 | |
| Abbvie INC. | $65.06 | 2021-2025 | |
| Lilly USA, LLC | $61.91 | 2020-2024 | Kisunla |
| Jazz Pharmaceuticals INC. | $47.37 | 2020-2025 | |
| Celgene Corporation | $40.97 | 2021-2024 | Zeposia |
| Acorda Therapeutics, INC | $40.11 | 2019 | |
| Lundbeck LLC | $36.70 | 2020-2023 | Rexulti |
| Emd Serono, INC. | $31.47 | 2019-2020 | |
| Argenx US, INC. | $31.34 | 2024 | Vyvgart Hytrulo |
| Vertex Pharmaceuticals Incorporated | $31.03 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.64 | 2025 | Hyqvia |
| Janssen Pharmaceuticals, INC | $28.14 | 2022 | |
| Neurelis, INC. | $26.69 | 2021 | |
| Greenwich Biosciences, INC. | $26.67 | 2019 | |
| Amgen INC. | $25.86 | 2025 | Uplizna |
| Kyowa Kirin, INC. | $24.56 | 2019-2020 | |
| Amylyx Pharmaceuticals, INC. | $23.32 | 2023 | Relyvrio |
| Catalyst Pharmaceuticals, INC. | $23.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.33 | 2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $20.81 | 2025 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $19.64 | 2025 | Crexont |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Pfizer INC. | $16.97 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $16.53 | 2021 | |
| Currax Pharmaceuticals LLC | $14.04 | 2021 | |
| Merz Pharmaceuticals, LLC | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Krendel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.